February 29, 2012 — Lantheus Medical Imaging Inc. announced a strategic distribution arrangement for its Definity cardiac ultrasound contrast agent in the People’s Republic of China, including Hong Kong S.A.R. and Macau S.A.R.

February 28, 2012 — According to a new study published in the American Journal of Roentgenology (AJR) in January 2012, molecular breast imaging (MBI), also known as breast-specific gamma imaging (BSGI), can detect cancers missed by the two most common breast imaging studies, mammography and ultrasound. BSGI had the highest overall sensitivity (91 percent) for breast cancer detection, significantly higher than that of mammography and ultrasound, 74 and 84 percent respectively.

February 24, 2012 — IRadimed Corp. announced the launch of the iMAGOX 2460 nonmagnetic magnetic resonance imaging (MRI) compatible SpO2 monitor with Masimo SET technology inside.

February 24, 2012 — A new imaging efficiency measure developed by the Centers for Medicare and Medicaid Services (CMS) to reduce computed tomography (CT) scans in emergency departments does not accurately determine which hospitals are performing CT scans inappropriately, according to a new study published online Annals of Emergency Medicine (“Assessment of Medicare's Imaging Efficiency Measure for Emergency Department Patients with Atraumatic Headache”).

February 24, 2012 — Positron Corp., through its wholly owned subsidiary, Manhattan Isotope Technology LLC (MIT), announced it had received its first shipment of strontium-82 (Sr-82) from the ARRONAX Cyclotron Facility in Nantes, France.

February 23, 2012 — Accelitech LLC announced its inaugural proton therapy project. The treatment center project, now under development, is the latest in Accelitech's ongoing effort to bring treatment technologies to more patients through joint-venture partnerships with physicians and hospitals.

February 24, 2012 — In a new study published in the March issue of Radiology, functional magnetic resonance imaging (fMRI) shows that cognitive rehabilitation changes brain function and improves cognitive performance in patients with relapsing-remitting multiple sclerosis (MS).

February 23, 2012 — A new look at the three most highly regarded prostate cancer treatment options is the first of its kind to consider long-term cost and quality of life post-treatment.